A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
Kulke, M Ruszniewski, P Van Cutsem, E Lombard-Bohas, C De Herder, W Pavel, M Degtyarev, E Brase, J Bubuteishvili-Pacaud, L
Kulke, M
Ruszniewski, P
Van Cutsem, E
Lombard-Bohas, C
De Herder, W
Pavel, M
Degtyarev, E
Brase, J
Bubuteishvili-Pacaud, L
Citations
Altmetric:
Abstract
Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily targeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generation SSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone in patients with advanced, well-differentiated, progressive pancreatic NET (pNET).
Description
Date
2017-03-06
Publisher
Collections
Keywords
Type
Article
Citation
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. 2017, Ann Oncol